Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H4Y5

UPID:
GSTO2_HUMAN

ALTERNATIVE NAMES:
Glutathione S-transferase omega 2-2; Glutathione-dependent dehydroascorbate reductase; Monomethylarsonic acid reductase

ALTERNATIVE UPACC:
Q9H4Y5; A8K771; B4DJW6; E7ESD6; Q49TW5; Q5GM70; Q5JU15; Q86WP3

BACKGROUND:
The protein Glutathione S-transferase omega-2, also known as Glutathione-dependent dehydroascorbate reductase and Monomethylarsonic acid reductase, exhibits significant enzymatic activities. These include high dehydroascorbate reductase activity, contributing to ascorbic acid recycling, and a role in the detoxification of inorganic arsenic by reducing MMA. Its enzymatic functions underscore its importance in cellular antioxidant defenses and detoxification processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Glutathione S-transferase omega-2 offers a promising avenue for the development of novel therapeutic approaches. Its key roles in antioxidant defense and detoxification pathways make it a valuable target for interventions aimed at bolstering cellular resilience against oxidative stress and toxic compounds.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.